Weight-loss drugs may reduce breast cancer risk by up to 30%, according to three studies, highlighting their potential role in lowering cancer development and mortality rates.
GLP-1 medications mimic a natural hormone called glucagon-like peptide-1
Jun 03, 2026
04:12 pm
What's the storyWeight-loss drugs, especially GLP-1 medications, have shown promising results in reducing the risk of developing and dying from breast cancer.
The findings were presented at the American Society of Clinical Oncology's annual meeting in Chicago.
Weight-loss drugs can cut breast cancer risk by up to 30%, studies suggest
Weight-loss drugs linked to lower breast cancer risk, study finds
GLP-1s may lower breast cancer risk in women by 30%, new study suggests
Women on GLP-1 drugs 30 percent less likely to develop breast cancer
Doctor breaks down study showing GLP-1s may lower breast cancer risk
GLP-1 drugs, including Ozempic, may have a beneficial effect across many types of cancer
Weight-loss jabs could cut breast cancer risk by nearly a third
Popular GLP-1 weight-loss drugs linked to lower risks of addiction and overdose
Medicamentos GLP-1 se asocian a un menor riesgo de cáncer de mama
Studio: farmaci dimagranti riducono rischio di tumore al seno
Three studies add to evidence that jabs could be part of cancer-fighting toolkit to cut risk of developing or dying from disease
Women on weight-loss medication may have a lower risk of developing breast cancer, according to a new study.
GLP-1 drugs commonly used for weight loss and diabetes decreased the risk of cancer spreading in patients with several different…
Stay up to date with notifications from The IndependentNotifications can be managed in browser…
Research from the Cleveland Clinic found that people who started a GLP-1 drug after their diagnosis were less likely to progress…
A new study found that some cancer patients who took GLP-1 drugs saw some remission — especially if they had breast cancer.
